Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/S0140-6736(05)78837-1 | DOI Listing |
Int Breastfeed J
January 2025
Division of Epidemiology & Biostatistics, Faculty of Medicine and Health Sciences, Stellenbosch University, Francie van Zijl Drive, PO Box 241, Cape Town, 8000, South Africa.
Background: Despite efforts to promote optimal breastfeeding practices, the practice of exclusive breastfeeding is low in South Africa. We conducted a trial to determine whether text messaging plus motivational interviewing prolonged exclusive breastfeeding during the first six months of life and improved child health outcomes.
Methods: We conducted a randomized parallel group-controlled trial between July 2022 and May 2024, at a secondary-level healthcare facility.
Breastfeed Med
January 2025
Department of Mathematics, Universitat Politècnica de Catalunya, Barcelona, Spain.
This study analyzes the impact and experiences of hospitalization for any reason on breastfeeding women. Cross-sectional online survey (November 2019-March 2020). Adults admitted to a Spanish hospital for at least one night, when actively breastfeeding, were included.
View Article and Find Full Text PDFBMC Psychol
January 2025
Pôle de Psychologie Sociale (PôPS), Unité Inserm U1296 Radiations : Défense, Santé, Environnement, Université Lyon 2, Bron, France.
Background: Breast cancer, a potential traumatic stressor, may be accompanied by positive changes, such as post-traumatic growth (PTG), which may allow patients to overcome this stressful event more easily. Our aim was to identify factors associated with PTG in breast cancer survivors (BCSs).
Methods: We conducted a cross-sectional study in Seintinelles volunteers who answered online questionnaires.
Breast Cancer Res
January 2025
Department of Medicine (Hematology/Oncology), School of Medicine, University of California San Francisco, 1450 Third St, San Francisco, CA, 94158, USA.
Background: Poly (ADP-Ribose) polymerase inhibitors are approved for treatment of tumors with BRCA1/2 and other homologous recombination repair (HRR) mutations. However, clinical responses are often not durable and treatment may be detrimental in advanced cancer due to excessive toxicities. Thus we are seeking alternative therapeutics to enhance PARP-directed outcomes.
View Article and Find Full Text PDFCancer Lett
January 2025
Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address:
The optimal breast cancer (BC) screening age in China remains uncertain. In this study, we evaluated the benefits, harms, and cost-effectiveness of lowering the screening starting age from 45 to 35 years and extending the stopping age from 64 to 79 years in Chinese women at an average risk of progressing BC. Biennial screening showed a lower incremental cost-effectiveness ratio (ICER) compared to annual screening.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!